101. Role of interleukin-2 and interleukin-6 in the mitogen responsiveness of T cells from patients with ‘common-variable’ hypogammaglobulinaemia
- Author
-
J. Farrant, A. D. B. Webster, and M. E. North
- Subjects
Interleukin 2 ,medicine.medical_specialty ,T-Lymphocytes ,medicine.medical_treatment ,T cell ,Immunology ,Mitosis ,chemical and pharmacologic phenomena ,Agammaglobulinemia ,Internal medicine ,Immunopathology ,medicine ,Humans ,Immunology and Allergy ,Phytohemagglutinins ,Interleukin 6 ,Phytohaemagglutinin ,biology ,Interleukin-6 ,Antibodies, Monoclonal ,Drug Synergism ,T lymphocyte ,Recombinant Proteins ,Endocrinology ,Cytokine ,medicine.anatomical_structure ,Cell culture ,biology.protein ,Interleukin-2 ,Mitogens ,Muromonab-CD3 ,Research Article ,medicine.drug - Abstract
SUMMARY We have assessed the ability of interleukin-2 (IL-2) and interleukin-6 (IL-6) to augment the proliferative response of T lymphocytes from ‘common-variable’ hypogammaglobulinaemia (CVH) patients and from normal controls, to the mitogens phytohaemagglutinin (PHA) and OKT3. We show that with cells from the control group and from those patients whose T cells respond to PHA within the control range, both IL-2 and IL-6 will significantly augment the response to OKT3. However, in those patients with a T cell defect in which the PHA response is below the control range, neither IL-2 nor IL-6 could restore the PHA or OKT3 response to normal. Responses to IL-2 or IL-6 alone were always in or above the control range.
- Published
- 1990
- Full Text
- View/download PDF